Meta-analysis of the prognostic value of long non-coding RNA PVT1 for cancer patients

Abstract

Background:Plasmacytoma variant translocation 1 (PVT1) is reported to be dysregulated in various cancers. Therefore, this meta-analysis was performed to clarify its utility as a prognosis marker in malignant tumors.Methods:Electronic databases, including PubMed, OVID, Cochrane Library, and Web of Science databases, were retrieved from inception to December 16, 2017. Typically, hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated, so as to explore the relationship between PVT1 expression and patient survival. In addition, odds ratios (OR) were calculated to assess the association of PVT1 expression with pathological parameters.Results:A total of 23 studies involving 2350 patients were included in this meta-analysis. The pooled HR suggested that high PVT1 expression levels were correlated with poor overall survival (OS, HR = 1.99, 95% CI: 1.73–2.28), disease-free survival (DFS, HR = 1.76, 95% CI: 1.45–2.14), and recurrence-free survival (RFS, HR = 1.74, 95% CI: 1.26–2.39) in cancer patients without obvious heterogeneity. Moreover, high PVT1 expression levels were also correlated with larger tumor size (OR = 1.47, 95% CI: 1.02–2.11), poor differentiation grade (OR = 1.79, 95% CI: 1.39–2.30), advanced tumor stage (pooled OR = 3.28, 95% CI: 2.46–4.38), lymph node metastasis (OR = 2.67, 95% CI: 1.66–4.29) and distant metastasis (OR = 4.00, 95% CI: 1.39–11.50) in cancer patients.Conclusions:Findings of this meta-analysis suggest that a high PVT1 expression level may serve as a novel biomarker of poor prognosis in cancers.

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

“…PVT1 can promote the development of glioma cells through various mechanisms, resulting in a worse prognosis for patients with glioma and high PVT1 expression [18,161,162]. Multiple meta-analyses have also shown that PVT1 can be used as a new tumor biomarker and a predictor of poor prognosis in different cancers [163][164][165][166][167].…”

Up-regulated lncRNA-PVT1 expression in peripheral blood mononuclear cells of patients with coronary artery disease is correlated with decreased interleukin-10 production

“…The level of PVT1 expression was signi cantly increased in cancers. A meta-analysis on a total of 23 studies reported that high PVT1 expression levels correlated with poor overall survival, larger tumor size, distant metastasis, and some other risk factors in cancer patients (21). In addition, it is found to be up-regulated in atrial muscle tissues from atrial brillation patients (22), and the myocardial tissues of sepsis rats (23).…”